Inhibition of antibody-dependent cell-mediated cytotoxicity (ADCC) as a means of detection of immune complexes in the sera of patients with thyroid disorders and bronchogenic carcinoma.
Circulating immune complexes in the sera of patients with thyroid disorders or bronchogenic carcinoma were investigated using an assay system based on the inhibition of the ADCC activity of rat spleen cells. Increased inhibition, as compared with that of the sera of age and sex matched controls, was found in patients with thashimoto thyroiditis, primary hypothyroidism and bronchogenic carcinoma. The degree of inhibition in the first two groups was markedly increased compared with control sera of the same IgG content. However, the results in the lung cancer group were slightly but not significantly greater than  in controls with the same level of IgG. Increased IgG levels were found in patients with thashimoto thyroiditis and thyrotoxicosis, and also in patients with bronchogenic  carcinoma who had mediastinal gland involvement. The lower level of sensitivity of the assay system was approximately 600 ng added aggregated IgG, corresponding to a concentration of 6mu g/ml in the sample assayed. It is possible that circulating immune complexes may exist in lung cancer, but at a level below that of the present assay system.
D000818:Animals; D000906:Antibodies; D000936:Antigen-Antibody Complex; D002283:Carcinoma, Bronchogenic / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008175:Lung Neoplasms / Q000276:immunology*; D051381:Rats / Q000276:immunology; D013154:Spleen / Q000276:immunology; D013959:Thyroid Diseases / Q000276:immunology*
D000906:Antibodies; D000936:Antigen-Antibody Complex; D007074:Immunoglobulin G